Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease –mineral and bone disorder?
ConclusionAdvanced CKD showed a trend of declining sclerostin levels and significantly higher CIMT levels. Serum sclerostin was not associated with CIMT. More studies are needed in order to reveal the exact role of sclerostin in the complexity of CKD –MBD pathophysiological mechanism.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
More News: Calcium | Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Epidemiology | Heart | Hormones | Study | Ultrasound | Urology & Nephrology